Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis

Neuropathology and Applied Neurobiology

Volumn 32, Issue 3, 2006, Pages 318-331

  Teunissen, C E ^a   Dijkstra, C D ^a   Jasperse, B ^a   Barkhof, F ^a   Vanderstichele, H ^b   Vanmechelen, E ^b   Polman, C H ^a   Bo L ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INNOGENETICS   (Belgium)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Axonal regeneration; CSF; GAP 43; Grey matter; Remyelination; White matter

Indexed keywords

NEUROMODULIN;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; FEMALE; GRAY MATTER; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTIPLE SCLEROSIS; NERVE FIBER GROWTH; NEUROFILAMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REMYELINIZATION; SYNAPTOGENESIS; WHITE MATTER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BRAIN; FEMALE; GAP-43 PROTEIN; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE REGENERATION;

EID: 33646113851     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2006.00730.x     Document Type: Article

References (57)

1. Trapp BD Peterson J Ransohoff RM Rudick R Mork S Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 338 278 85
2. Ferguson B Matyszak MK Esiri MM Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997 120 393 9
3. Mancardi G Hart B Roccatagliata L Brok H Giunti D Bontrop R Massacesi L Capello E Uccelli A. Demyelination and axonal damage in a non-human primate model of multiple sclerosis. J Neurol Sci 2001 184 41 9
4. Kalkers NF Ameziane N Bot JC Minneboo A Polman CH Barkhof F. Longitudinal brain Volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002 59 1572 6
5. Kornek B Storch MK Weissert R Wallstroem E Stefferl A Olsson T Linington C Schmidbauer M Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000 157 267 76
6. Bitsch A Schuchardt J Bunkowski S Kuhlmann T Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000 123 1174 83
7. Medana I Martinic MA Wekerle H Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001 159 809 15
8. Nicot A Ratnakar PV Ron Y Chen CC Elkabes S. Regulation of gene expression in experimental autoimmune encephalomyelitis indicates early neuronal dysfunction. Brain 2003 126 398 412
9. Pitt D Werner P Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000 6 67 70
10. Lappe-Siefke C Goebbels S Gravel M Nicksch E Lee J Braun PE Griffiths IR Nave KA. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003 33 366 74
11. Kornek B Storch MK Bauer J Djamshidian A Weissert R Wallstroem E Stefferl A Zimprich F Olsson T Linington C Schmidbauer M. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 2001 124 1114 24
12. Moll C Mourre C Lazdunski M Ulrich J. Increase of sodium channels in demyelinated lesions of multiple sclerosis. Brain Res 1991 556 311 16
13. De Stefano N Matthews PM Fu L Narayanan S Stanley J Francis GS Antel JP Arnold DL. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998 121 1469 77
14. Turner B Lin X Calmon G Roberts N Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003 9 21 7
15. Truyen L van Waesberghe JH van Walderveen MA van Oosten BW Polman CH Hommes OR Ader HJ Barkholf F. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996 47 1469 76
16. Bjartmar C Wujek JR Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003 206 165 71
17. Charcot M. Histology of the sclerotic plaque [in French]. Gaz Hosp 1868 141 554 8
18. Greenfield J King L. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 1936 59 445 58
19. Kerschensteiner M Bareyre FM Buddeberg BS Merkler D Stadelmann C Bruck W Misgeld T Schwab ME. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med 2004 200 1027 38
20. Oestreicher AB De Graan PN Gispen WH Verhaagen J Schrama LH. B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system. Prog Neurobiol 1997 53 627 86
21. Hens JJ Ghijsen WE Weller U Spierenburg HA Boomsma F Oestreicher AB Lopes de Silva FH De Graan PN. Anti-B-50 (GAP-43) antibodies decrease exocytosis of glutamate in permeated synaptosomes. Eur J Pharmacol 1998 363 229 40
22. Aigner L Caroni P. Absence of persistent spreading, branching, and adhesion in GAP-43-depleted growth cones. J Cell Biol 1995 128 647 60
23. Aigner L Arber S Kapfhammer JP Laux T Schneider C Botteri F Brenner HR Caroni P. Overexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice. Cell 1995 83 269 78
24. Mori N Morii H. SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. J Neurosci Res 2002 70 264 73
25. Bogdanovic N Davidsson P Volkmann I Winblad B Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative study. J Neural Transm 2000 107 463 78
26. Yamanouchi H Mizuguchi M Oka A Takashima S Becker LE Eguchi M Nakazato Y. Enhanced GAP-43 gene expression in cortical dysplasia. Neuroreport 2000 11 1815 19
27. Kage M Ikemoto A Akiguchi I Kimura J Matsumoto S Kimura H Tooyama I. Primary structure of GAP-43 mRNA expressed in the spinal cord of ALS patients. Neuroreport 1998 9 1403 6
28. Ueki A Namba Y Otsuka M Okuno M Nishimura M Oda M Ikeda K. GAP-43 immunoreactivity is detected in the nerve terminals of patients with amyotrophic lateral sclerosis. Ann Neurol 1993 33 226 7
29. Perrone-Bizzozero NI Sower AC Bird ED Benowitz LI Ivins KJ Neve RL. Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. Proc Natl Acad Sci USA 1996 93 14182 7
30. Sjogren M Davidsson P Gottfries J Vanderstichele H Edman A Vanmechelen E Wallin A Blennow K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001 12 257 64
31. De Groot CJ Bergers E Kamphorst W Ravid R Polman CH Barkhof F van der Valk P. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 2001 124 1635 45
32. Meiri KF Bickerstaff LE Schwob JE. Monoclonal antibodies show that kinase C phosphorylation of GAP-43 during axonogenesis is both spatially and temporally restricted in vivo. J Cell Biol 1991 112 991 1005
33. Mercken M Lubke U Vandermeeren M Gheuens J Oestreicher AB. Immunocytochemical detection of the growth-associated protein B-50 by newly characterized monoclonal antibodies in human brain and muscle. J Neurobiol 1992 23 309 21
34. Olsson A Vanderstichele H Andreasen N De Meyer G Wallin A Holmberg B Rosengren L Vanmechelen E Blennow K. Simultaneous measurement of A{beta} (1-42), total Tau, and phosphorylated Tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2004
35. Ulvestad E Williams K Bo L Trapp B Antel J Mork S. HLA class II molecules (HLA-DR-DP-DQ) on cells in the human CNS studied in situ and in vitro. Immunology 1994 82 535 41
36. Bö L Mork S Kong PA Nyland H Pardo CA Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994 51 135 46
37. Osen-Sand A Catsicas M Staple JK Jones KA Ayala G Knowles J Grenningloh G Catsicas S. Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo. Nature 1993 364 445 8
38. Sze CI Bi H Kleinschmidt-DeMasters BK Filley CM Martin LJ. Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's disease brains. J Neurol Sci 2000 175 81 90
39. Greber S Lubec G Cairns N Fountoulakis M. Decreased levels of synaptosomal associated protein 25 in the brain of patients with Down syndrome and Alzheimer's disease. Electrophoresis 1999 20 928 34
40. Dessi F Colle MA Hauw JJ Duyckaerts C. Accumulation of SNAP-25 immunoreactive material in axons of Alzheimer's disease. Neuroreport 1997 8 3685 9
41. Whitney LW Becker KG Tresser NJ Caballero-Ramos CI Munson PJ Prabhu VV Trent JM McFarland HF Biddison WE. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann Neurol 1999 46 425 8
42. Penkowa M Hidalgo J. Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimmune encephalomyelitis. J Neurosci Res 2003 72 574 86
43. de la Monte SM Ng SC Hsu DW. Aberrant GAP-43 gene expression in Alzheimer's disease. Am J Pathol 1995 147 934 46
44. Gianola S Rossi F. GAP-43 overexpression in adult mouse Purkinje cells overrides myelin-derived inhibition of neurite growth. Eur J Neurosci 2004 19 819 30
45. Bomze HM Bulsara KR Iskandar BJ Caroni P Skene JH. Spinal axon regeneration evoked by replacing two growth cone proteins in adult neurons. Nat Neurosci 2001 4 38 43
46. Kuhlmann T Lingfeld G Bitsch A Schuchardt J Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002 125 2202 12
47. Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci 2003 4 703 13
48. Irwin N Chao S Goritchenko L Horiuchi A Greengard P Nairn AC Benowitz LI. Nerve growth factor controls GAP-43 mRNA stability via the phosphoprotein ARPP-19. Proc Natl Acad Sci USA 2002 99 12427 31
49. John GR Lee SC Brosnan CF. Cytokines: powerful regulators of glial cell activation. Neuroscientist 2003 9 10 22
50. Yin Y Cui Q Li Y Irwin N Fischer D Harvey AR Benowitz LI. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci 2003 23 2284 93
51. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 3 23 35
52. Mantovani A Sozzani S Locati M Allavena P Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002 23 549 55
53. Peterson JW Bo L Mork S Chang A Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001 50 389 400
54. Bö L Vedeler CA Nyland H Trapp BD Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003 9 323 31
55. Brink BP Veerhuis R Breij EC van der Valk P Dijkstra CD Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005 64 147 55
56. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003 4 299 309
57. Raisman G. Myelin inhibitors: does NO mean GO? Nat Rev Neurosci 2004 5 157 61